business
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Key takeaways
- Just a few days after a well-received initial public offering, a director of drug developer Parabilis Medicines (NASDAQ:PBLS) bought shares in the open market.
- Director Alan Sebulsky disclosed the purchase of 17,500 shares in multiple open-market transactions on June 12 and June 15, 2026, for a total consideration of approximately $474,000, according to the SEC Form 4 filing.
- Transaction value based on SEC Form 4 weighted average purchase price ($27.06); post-transaction value based on June 18, 2026 market close ($25.85).
Just a few days after a well-received initial public offering, a director of drug developer Parabilis Medicines (NASDAQ:PBLS) bought shares in the open market.
Director Alan Sebulsky disclosed the purchase of 17,500 shares in multiple open-market transactions on June 12 and June 15, 2026, for a total consideration of approximately $474,000, according to the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($27.06); post-transaction value based on June 18, 2026 market close ($25.85).
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop